Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

David Cunningham, Yves Humblet, Salvatore Siena et al. · New England Journal of Medicine · 2004 · 5K citations · Full text

Medicine, Oncology, Pharmacology +17

Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Rafael G. Amado, Michael Wolf, Marc Peeters et al. · Journal of Clinical Oncology · 2008 · 3.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

<i>KRAS</i> Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

Astrid Lièvre, Jean‐Baptiste Bachet, Valérie Boige et al. · Journal of Clinical Oncology · 2008 · 1.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Expression of Epiregulin and Amphiregulin and <i>K-ras</i> Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

Shirin Khambata‐Ford, Christopher R. Garrett, Neal J. Meropol et al. · Journal of Clinical Oncology · 2007 · 1.1K citations · Full text

Medicine, Genetics, Oncology +17

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

Wendy De Roock, Hubert Piessevaux, Joris De Schutter et al. · Annals of Oncology · 2007 · 827 citations · Full text

Medicine, Oncology, Radiology +12